Peer-reviewed veterinary case report
Fibroblast growth factor 23 and SDMA levels in older cats
By Sargent, Hannah J et al.·Published in Journal of veterinary internal medicine·2019·Department of Comparative Biomedical Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Fibroblast growth factor 23 and symmetric dimethylarginine concentrations in geriatric cats.
- Species:
- cat
Plain-English summary
A group of older cats without kidney disease were tested for two important blood markers, FGF23 and SDMA, to see how they relate to each other. The results showed that cats with higher SDMA levels also had higher FGF23 levels, which could indicate early changes in kidney function. This suggests that monitoring these markers might help veterinarians catch kidney issues sooner in geriatric cats. Further research is needed to understand these changes better and how they can help manage early kidney disease in cats.
People also search for: cat kidney disease symptoms · geriatric cat blood test results · high SDMA levels in cats
Abstract
BACKGROUND: Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone that is increased in azotemic cats with chronic kidney disease (CKD) and predictive of the onset of azotemia in older cats. The introduction of symmetric dimethylarginine (SDMA) as a biomarker of glomerular filtration rate has led to the identification of cats in which SDMA is increased, but plasma creatinine concentrations remains within reference range. There is currently little understanding of the metabolic changes present in such cats. OBJECTIVES: To examine the relationship between plasma FGF23 and SDMA concentrations in non-azotemic geriatric cats. ANIMALS: Records of a cross section of client-owned cats (n = 143) without azotemic CKD. METHODS: Clinicopathological information was obtained from cats (≥ 9 years) from records of 2 first opinion practices. The relationship between plasma SDMA and FGF23 concentrations was examined using Spearman's correlation and variables compared using the Mann-Whitney U test. RESULTS: Cats with increased SDMA concentrations had significantly higher plasma FGF23 (P < .001) and creatinine (P < .001) concentrations compared to cats with SDMA concentrations within reference range. A weak positive relationship was demonstrated between plasma FGF23 and SDMA concentrations (r = .35, P < .001) and between plasma FGF23 and creatinine (r = .23, P = .005) concentrations. CONCLUSIONS AND CLINICAL IMPORTANCE: More cats with increased SDMA concentrations had higher FGF23 concentrations than those with SDMA concentrations within the reference range, suggesting the presence of an alteration in phosphate homeostasis. Further studies are warranted to identify influencing factors and to explore the utility of FGF23 concentration to inform management of cats with early stage CKD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31568615/